PESCE, A. Why pharmacogenetic testing should be reimbursed by Medicare and commercial health insurance. Journal of Opioid Management, [S. l.], v. 20, n. 4, p. 267, 2024. DOI: 10.5055/jom.0870. Disponível em: https://wmpllc.org/ojs/index.php/jom/article/view/3677. Acesso em: 24 nov. 2024.